Risks

ARQT’s leverage remains manageable but above cash-rich dermatology peers, so refinancing or covenant sensitivity could constrain flexibility if commercialization spending stays elevated.

Interest coverage is positive yet modest versus larger specialty-drug peers, making earnings volatility more likely to pressure funding capacity during slower-than-expected uptake.

The very long cash conversion cycle signals working-capital drag, which can absorb liquidity and leave ARQT less resilient than peers with faster inventory and receivables turns.

Dependence on a concentrated dermatology franchise leaves ARQT more exposed than diversified peers to payer access shifts, formulary pressure, or slower prescription conversion.

Because free cash flow is not yet established, ARQT has less self-funding capacity than profitable peers, increasing reliance on external capital if growth or margins disappoint.

Opportunities

ARQT’s current ratio and quick ratio are strong versus many biotech peers, giving it better near-term liquidity to support launch execution and absorb volatility.

Moderate leverage relative to equity suggests ARQT has more balance-sheet capacity than highly indebted peers to fund commercialization and working-capital needs.

If dermatology demand continues to expand, ARQT can convert operating leverage faster than larger, slower-growing peers because a focused franchise can scale with less complexity.

Compared with earlier-stage biotech peers, ARQT’s positive interest coverage indicates a more credible operating base, which can improve access to capital and partner confidence.

The company’s specialty-dermatology positioning aligns with a structurally attractive niche, where differentiated products can sustain pricing and prescription growth better than commoditized peers.

Overall Score

ARQT’s strong liquidity and focused dermatology positioning support upside versus peers, while working-capital intensity and only moderate coverage keep financing and execution risks meaningful.